The importance of an independent validation cohort for metabolomics biomarker studies-Reference-Cited by-同舟云学术

The importance of an independent validation cohort for metabolomics biomarker studies

Published:2018-05 Issue:5 Volume:33 Page:856-856
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Trezzi Jean-Pierre¹²,Hiller Karsten³⁴,Mollenhauer Brit⁵

Affiliation:

1. Integrated Biobank of Luxembourg; Dudelange Luxembourg

2. Luxembourg Center for Systems Biomedicine; avenue de l'Université; Esch-sur-Alzette Luxembourg

3. Braunschweig Integrated Centre for Systems Biology (BRICS); Technische Universität Braunschweig; Germany

4. Helmholtz Centre for Infection Research; Braunschweig Germany

5. Paracelsus-Elena Klinik, Kassel and University Medical Center; Goettingen Germany

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference4 articles.

1. Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease;Trezzi;Mov Disord,2017

2. investigators. Metabolomic biomarkers strongly differentiate PD from healthy controls (HCs) in BioFIND study* specimens [abstract];LeWitt;Mov Disord,2017

3. The BioFIND study: characteristics of a clinically typical Parkinson's disease biomarker cohort;Kang;Mov Disord,2016

4. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort;Mollenhauer;Neurology,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations;Journal of Parkinson's Disease;2021-04-13

2. Mass spectrometry-based metabolomics for an in-depth questioning of human health;Advances in Clinical Chemistry;2020

3. A metabolomic signature of treated and drug-naïve patients with Parkinson’s disease: a pilot study;Metabolomics;2019-06

4. Cerebrospinal fluid biomarker for Parkinson's disease: An overview;Molecular and Cellular Neuroscience;2019-06